InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference

Focused on Extending the Human Lifespan, the bioinformatics company is one of 12 rising star technology companies recognized as the most promising GPU-fueled Startup

SAN JOSE, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- via PRWEB - While deep learning was the topic of many conversations at last week's 2015 GPU technology conference (GTC), the CEO of one start-up spoke passionately about using fast GPUs to fight cancer and push the human lifespan well beyond the generally-agreed ceiling of 120 years.

Insilico Medicine, a Baltimore MD informatics company, is one of 12 companies recognized as the hottest GPU-powered startups in the US.

While other startups in the GTC Emerging Companies Summit have business models focused on self-driving cars, gaming, animation, or imaging, Insilico Medicine is the only start-up using GPU technology to fight age-related diseases such as cancer or Alzheimer's.

"We live in a very exciting time when information technology is converging with biotechnology," said Alex Zhavoronkov, PhD, the CEO of Insilico Medicine. "We developed a bioinformatics platform and strategy to tackle humanity's greatest challenge - aging and age-related diseases and we're honored to be recognized by NVIDIA as a promising GPU-powered startup."

Until the early 1990s, biology and related fields required very little experience with computers. Now, however, the vast amount of DNA and molecular data generated from the Human Genome Project and labs around the world have made high-powered computer analysis necessary. Because GPU-accelerated computing is the fastest way to analyze data, Insilico Medicine has received a great deal of attention in recent weeks from pharmaceutical companies and investors. Medical researchers agree GPU computing and computer science will play a key role in finding cures for age-related diseases and extending the human lifespan.

"Aging is humanity's most complex and daunting medical problem and it has defeated us for too long," said Dr. Aubrey de Grey, a gerontology expert and the Chief Science Officer of the SENS Research Foundation. "We will overcome it with a trifecta of new technologies, new insights - and new data analysis tools, an area at which Insilico Medicine promises to be at the forefront."

the 11 GPU-powered companies joining Insilico Medicine include Artomax, Ersatz Labs, FluiDyna, GeekSys, Intempora, NE Scientific, Pythia Systems, QM Scientific, Redshift Rendering Technologies, Replica Labs, and SYSTAP.

"To analyze how cancer cells respond to certain treatments, you must run drug scoring algorithms on high-end big data computer systems," said Zhavoronkov. "And no one can manage this work more effectively than our team of experts in both computer science and bioscience."

About Insilico Medicine

Insilico Medicine, Inc. is a Baltimore-based company utilizing advances in genomics and big data analysis for in silico drug discovery and drug repurposing for aging and age-related diseases. The company utilizes the GeroScope™, OncoFinder™ , Pathway Cloud Intelligence™ and PharmAtlas™ packages for aging and cancer research, pursues internal drug discovery programs, and provides services to pharmaceutical companies.

If you have any questions about the science of aging, bioinformatics, or Insilico Medicine's plan to use GPUs in anti-aging research and drug discovery, please call (443) 451- 7212 or visit:

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit


Contact Data